Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25240875 | 0.90 | CYP2D6 (0.49) | CYP2D6CYP2C9CYP2C19TP53HPGD | |
| SCHEMBL25250785 | 0.79 | CYP1A2 (0.50) | CYP2C9CYP2C19TP53HPGDL3MBTL1 | |
| SCHEMBL25215953 | 0.76 | NFATC1 (0.46) | NFATC1MAPTCTNNB1WNT3A | |
| SCHEMBL10753454 | 0.76 | NFATC1 (0.61) | KDM4ENFATC1MAPT | |
| SCHEMBL25208727 | 0.75 | FEN1 (0.48) | NFATC1CTNNB1WNT3A | |
| SCHEMBL25213631 | 0.75 | CNR1 (0.54) | PKMNPC1MAPT | |
| SCHEMBL25248095 | 0.75 | TP53 (0.47) | TP53NFATC1POLB | |
| SCHEMBL25221451 | 0.74 | POLB (0.50) | TP53PKMNFATC1MAPTPOLB | |
| SCHEMBL25212820 | 0.74 | CYP19A1 (0.59) | CYP2C9CYP2C19TP53HPGDPKM | |
| SCHEMBL25250699 | 0.74 | CYP19A1 (0.59) | TP53KDM4EMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250093329-A1 | SCREENING OF COMPOUNDS | THE UNIVERSITY OF TULSA | 2025-03-20 | — | — | US | disclosed |
| EP-4469592-A1 | SCREENING OF COMPOUNDS | The University Of Tulsa (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230266302-A1 | SYNTHESIS AND USE OF N-BENZYL SULFONAMIDES | THE UNIV OF TULSA (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2023146904-A1 | SCREENING OF COMPOUNDS | THE UNIVERSITY OF TULSA (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4185706-A1 | SYNTHESIS AND USE OF N-BENZYL SULFONAMIDES | The University Of Tulsa (US) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230266302-A1 | SYNTHESIS AND USE OF N-BENZYL SULFONAMIDES | ATP5ME, ATP5F1B, ATP5MG | CYP2D6 354/4885CYP2C9 571/4885CYP2C19 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.